>
Fa   |   Ar   |   En
   Omalizumab For Treatment of Chronic Urticaria: A Review of Effective Dose  
   
نویسنده Ghaffari Javad ,Ghaffari Negar
منبع Pharmaceutical And Biomedical Research - 2019 - دوره : 5 - شماره : 1 - صفحه:1 -5
چکیده    Omalizumab (, xolair®) a humanized antiige monoclonal antibody, is effective and welltolerated in patients with chronic spontaneous urticaria refractory to h1 antihistamines. the web search of several databases, including pubmed, embase, scopus, google, sid, magiran, and irandoc, led to the selection of 60 articles. the search process was performed using the keywords of xolair, omalizumab, urticaria, chronic urticaria, effect, and treatment. all studies have been conducted on people over 12 years of age with the exception of 2 articles investigating patients over 7 years old. most studies have been performed on patients within the age range of 1275 years and the maximum age of 81 years. omalizumab has been administered at different doses for patients with chronic urticaria (75600 mg). it has been shown to have a positive effect at all administered doses; however, it has the greatest effect when administered at the dose of 300 mg. the interval of subcutaneous injections was 26 weeks. in conclusion, the administration of this drug is effective at doses of 150 and 300 mg although the most effective dose is 300 mg.
کلیدواژه Chronic Urticaria ,Omalizumab ,Treatment ,Anti-Ige ,Xolair®
آدرس Mazandaran University Of Medical Sciences, Pediatric Infectious Diseases Research Center, Faculty Of Medicine, Iran, Mazandaran University Of Medical Sciences, Iran
پست الکترونیکی negarghaffari96@gmail.com
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved